Sun Pharma Advanced Research Company · NSE: SPARC · BSE: 532872
Q2 FY22 results · Jul–Sep 2021
Sun Pharma Advanced Research Company reported revenue from operations of ₹27.87 crore (up 58.0% from Q2 FY21) and net loss of ₹55.14 crore for Q2 FY22 (Jul–Sep 2021), on a standalone basis.
| Item | Q2 FY22 | Q2 FY21 | YoY | Q1 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 27.87 | 17.64 | +58.0% | 21.99 | +26.7% |
| Other income | 5.98 | 2.82 | +112.1% | 0.80 | +647.5% |
| Total income | 33.85 | 20.46 | +65.4% | 22.79 | +48.5% |
| Profit before tax | (55.14) | (83.49) | Loss narrowed | (61.37) | Loss narrowed |
| Net profit for the period | (55.14) | (83.49) | Loss narrowed | (61.37) | Loss narrowed |
| EPS, basic (₹) | (2.09) | (3.19) | Loss narrowed | (2.34) | Loss narrowed |
| Net margin (%) | -197.8 | -473.3 | -279.1 |
Standalone
- Filed with BSE
- 02 Nov 2021, 18:41 IST
- Board meeting
- 01 Nov 2021
- Period
- 01 Jul 2021 to 30 Sep 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE